CNS Pharmaceuticals approves 2020 Equity Plan amendment
- Increased shares authorized under 2020 Equity Plan by 650,000
- Stockholders ratified MaloneBailey, LLP as accounting firm
- 6 directors elected for 2027 Annual Meeting
CNSP
CNS Pharmaceuticals, Inc. SEC filings
Every EDGAR filing for CNS Pharmaceuticals, Inc. (CNSP), newest first, with AI summaries and stories.
- Ticker
- CNSP
- CIK
- 1729427
- Sector
- Biotech and pharma
- Latest filing
- Oct 2
Next: earnings expected ~Nov 16 ยท 10-Q expected ~Nov 16 (deadline Nov 16)
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
MAJOR8-KCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINEDEFA14ACNS Pharmaceuticals, Inc.CNSPLIVE ROUTINEDEF 14ACNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE4CNS Pharmaceuticals, Inc.CNSPLIVE 3 insider filings
Michal Fisher, insider filing for CNSP
Show all 3
- 4Insider filing for CNSP
- 3New insider at CNSP
- 4Insider filing for CNSP
Michal Fisher, reporting
ROUTINESCHEDULE 13G/ACNS Pharmaceuticals, Inc.CNSPLIVE Ownership stake disclosure by Ikarian Capital, LLC (amended)
Ikarian Capital, LLC, filed by
NOTABLE10-QCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE8-KCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINEEFFECTCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE424B3CNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE4CNS Pharmaceuticals, Inc.CNSPLIVE Faith L. Charles, insider filing for CNSP
Faith L. Charles, reporting
ROUTINEDCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINES-3CNS Pharmaceuticals, Inc.CNSPLIVE ROUTINESCHEDULE 13G/ACNS Pharmaceuticals, Inc.CNSPLIVE Ownership stake disclosure by Stonepine Capital Management, LLC (amended)
Stonepine Capital Management, LLC, filed by
NOTABLE10-QCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE8-KCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE10-K/ACNS Pharmaceuticals, Inc.CNSPLIVE ROUTINESCHEDULE 13GCNS Pharmaceuticals, Inc.CNSPLIVE Ownership stake disclosure by Ikarian Capital, LLC
Ikarian Capital, LLC, filed by
NOTABLE10-KCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE8-KCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE4CNS Pharmaceuticals, Inc.CNSPLIVE 4 insider filings
Eric Faulkner, insider filing for CNSP
Show all 4
- 4Insider filing for CNSP
- 3New insider at CNSP
- 4Insider filing for CNSP
- 3New insider at CNSP
Eric Faulkner, reporting
ROUTINE8-KCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINES-8CNS Pharmaceuticals, Inc.CNSPLIVE ROUTINE8-KCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINESCHEDULE 13G/ACNS Pharmaceuticals, Inc.CNSPLIVE Ownership stake disclosure by Stonepine Capital Management, LLC (amended)
Stonepine Capital Management, LLC, filed by
ROUTINE4CNS Pharmaceuticals, Inc.CNSPLIVE 2 insider filings
Rami Levin, insider filing for CNSP
Show all 2
- 4Insider filing for CNSP
- 3New insider at CNSP
Rami Levin, reporting
ROUTINE8-KCNS Pharmaceuticals, Inc.CNSPLIVE MAJOR8-KCNS Pharmaceuticals, Inc.CNSPLIVE CNS Pharmaceuticals, Inc. reported: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
ROUTINE4CNS Pharmaceuticals, Inc.CNSPLIVE 7 insider filings
Jerzy Gumulka, insider filing for CNSP
Show all 7
- 4Insider filing for CNSP
- 4Insider filing for CNSP
- 4Insider filing for CNSP
- 4Insider filing for CNSP
- 4Insider filing for CNSP
- 4Insider filing for CNSP
- 4Insider filing for CNSP
Jerzy Gumulka, reporting
ROUTINESCHEDULE 13G/ACNS Pharmaceuticals, Inc.CNSPLIVE CNS Pharmaceuticals, Inc. (CNSP) filed a Schedule 13G/A, disclosing that Armistice Capital, LLC has increased its ownership stake in the company to over 5%.
ARMISTICE CAPITAL, LLC, filed by
NOTABLE10-QCNS Pharmaceuticals, Inc.CNSPLIVE ROUTINEDEFA14ACNS Pharmaceuticals, Inc.CNSPLIVE ROUTINESCHEDULE 13GCNS Pharmaceuticals, Inc.CNSPLIVE Ownership stake disclosure by Stonepine Capital Management, LLC
Stonepine Capital Management, LLC, filed by